AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02234726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Childhood Development Program
Description: A cadre of community-based health workers, Child Development Agents (CDAs), have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases and referral for diagnosis and treatment; and 4) organization and mentoring of weekly meetings for caregivers to discuss parenting issues and promote early childhood cognitive stimulation.~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits.
Study NCT02559648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated.
Study NCT02974036 — intervention group
Intervention type: OTHER
Intervention: Patient education for osteoarthritis
Description: Group sessions and optional supervised exercise.
Study NCT02400671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS messaging
Study NCT03880773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stapler
Description: for transection of the pancreas and pancreatic stump treatment
Study NCT03880773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic shears
Description: for transection of the pancreas and pancreatic stump treatment
Study NCT02559648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated.
Study NCT05542459 — intervention group
Intervention type: DRUG
Intervention: Biologics
Description: Infliximab, adalimumab, vedolizumab, ustekinumab, and other biologics approved for IBD
Study NCT03037866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeSkills Training for College
Description: The intervention will consist of e-learning modules (self-guided) and small-group sessions (facilitator led). The intervention is designed for new college students and is aimed at providing tools and strategies to help them maximize opportunities and adeptly handle the challenges ahead. The intervention will teach them the knowledge and skills needed to stay safe from problems that are prevalent among new students on college campuses, such as alcohol and drug abuse and sexual violence.
Study NCT03087175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGuard stent
Description: MGuard micronet mesh-covered stent in treatment of STE and NSTE-ACS
Study NCT03087175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug eluting stent and bare metal stent
Description: Drug eluting stent and bare metal stent in treatment of STE and NSTE-ACS For example, Resolute Onyx
Study NCT02129712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Study NCT03830086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures, together with Sufentanil
Study NCT02129712 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive training
Study NCT04653974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Needle-free injection
Description: This study was performed among children aged 4-11 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 70 patients were evaluated in accordance with the exclusion criteria and 56 children (31 girls and 25 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the Wong-Baker Pain Scale at three time points: immediately after injection (Pain 1), during treatment (Pain 2), and at the end of the treatment (Pain 3).
Study NCT01119287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1% ophthalmic suspension
Description: Maxidex
Study NCT04688866 — intervention group
Intervention type: OTHER
Intervention: Sequencing
Description: This is an observational study, since the assignment of the medical intervention (e.g. cerclage or pessary) is not at the discretion of the investigator. However, cervical samples collected from both groups are subjected to amplicon sequencing for taxonomic classification of microorganisms.
Study NCT01119287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1% ophthalmic solution
Description: Patanol
Study NCT01119287 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inactive ingredients, used as placebo
Description: Tears Naturale II
Study NCT04731948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: 400µg Folic Acid per day for 16 weeks
Study NCT04731948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: 400µg Folic Acid per day for 16 weeks
Study NCT04957004 — intervention group
Intervention type: DEVICE
Intervention: CPAP
Description: CPAP ventilator was worn at nigh
Study NCT03172442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum plate
Description: Vacuum plate with two hooks between lateral incisor and canine in each side will be applied on the lower arch.
Study NCT03172442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expander
Description: Rapid maxillary expander will be applied in the maxilla to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.
Study NCT03172442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Class III elastics
Description: Class III elastic traction from upper first molar to the hook in both side will be applied.
Study NCT01424943 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stepping Stones Triple P
Description: 10-12 session manualized intervention delivered in client homes
Study NCT01687582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 analog
Description: GLP-1 analog treatment
Study NCT01424943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P
Description: 10-12 session manualized intervention delivered in client homes
Study NCT01424943 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: BabyNet Services As usual
Description: BabyNet services as usual based on IFSP
Study NCT04130412 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open release
Description: Open release of lateral retinaculae
Study NCT03903744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioneuroablation
Description: The electroanatomical map of the right (RA) and left (LA) atrium will be created and anatomically-based ablation of GP will be performed. Ablation in the RA is started from the supero-posterior area (superior right atrial GP), to the middle-posterior area (posterior right atrial GP). In the LA, ablation is started at the site of the anterior right GP and is continued downwards along the anterior part of a common vestibulum of the right pulmonary veins (PV), opposite to the right-sided ablation lesions. Finally, area of right inferior GP, close to the RIPV is ablated under intracardiac echocardiography control. Using this technique, GP's located close to the left PV are not ablated. We use a pure anatomic approach without identification of GP.
Study NCT03601208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mitra
Description: When the patients have their bloods done through venepuncture, an additional 5-10mls will be taken (one EDTA bottle for tacrolimus and one serum bottle for creatinine; and two Mitra VAMs). Patients will also have a fingerprick test and 20 microlitres of blood taken using Mitra volumetric absorptive microsampling (VAMs)
Study NCT03912610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Functional magnetic resonance examination
Description: Functional magnetic resonance examination by a Ultra high field magnetic resonance instrument named MAGNATOM 7T.
Study NCT00537472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose bupivicaine in spinal anesthetic
Description: Bupivacaine 9 mg intrathecal single shot injection at start of surgery
Study NCT00537472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose bupivacaine in spinal anesthetic
Description: Bupivacaine 13 mg intrathecal single shot injection at start of surgery
Study NCT01175343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO
Study NCT01175343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02398526 — intervention group
Intervention type: DRUG
Intervention: Radium-223 dichloride, (Xofigo, BAY88-8223)
Description: Dosage and treatment duration according to the decision of the treating physician
Study NCT03273907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyPass Micro-Stent implanted with CyPass 241-S applier
Description: CyPass System (Model 241-S) consists of the CyPass Micro-Stent contained in a loading device (loader) and the CyPass applier.The CyPass Micro-Stent is an implantable medical device intended for long term use.
Study NCT04446000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL730
Description: solution for injection and infusion
Study NCT02041091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tabalumab Auto-Injector
Description: Administered SC
Study NCT02041091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tabalumab Prefilled Syringe
Description: Administered SC
Study NCT04553861 — intervention group
Intervention type: DEVICE
Intervention: Ambulatory blood pressure monitoring
Description: Every 30 minutes from 7 AM to 10 PM and every 1 hour from 10 PM to 7 AM
Study NCT04731948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2 µg Vitamin B12
Description: 2 µg Vitamin B12 per day for 16 weeks
Study NCT04731948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 10 µg Vitamin B12
Description: 10 µg Vitamin B12 per day for 16 weeks
Study NCT04731948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 50 µg Vitamin B12
Description: 50 µg Vitamin B12 per day for 16 weeks
Study NCT04589520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeartBot App
Description: HeartBot is an app designed to enable people 14 years and older to use relaxation tools offered by Heartfulness to deal with daily stress and anxiety in a healthy, productive manner.
Study NCT04626011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extractions
Description: After blood collection tests, Periodontal analysis, Orthopantomography and Anamnestic record each group will receive a full mouth disinfection and needed extractions.
Study NCT01969461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Description: The 4-session MET intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the clinic or the home by a CHW (outreach worker, etc) already providing services in the clinic. In sessions 1 and 2 (each behavior will get its own session), CHW will elicit the client's view of the problem using MI techniques, building motivation for change by eliciting and reinforcing change talk. The CHW will deliver feedback and discuss the consideration of a behavior change plan option, and the client sets the change plan goal and consolidates commitment. In the last two sessions, the CHW will review the change plan, continue to elicit and reinforce change talk, problem-solve barriers, consolidate commitment, and consider strategies to maintain behavior change.
Study NCT01969461 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement Therapy (MET)
Description: The 4-session MET intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the clinic or the home by a CHW (outreach worker, etc) already providing services in the clinic. In sessions 1 and 2 (each behavior will get its own session), CHW will elicit the client's view of the problem using MI techniques, building motivation for change by eliciting and reinforcing change talk. The CHW will deliver feedback and discuss the consideration of a behavior change plan option, and the client sets the change plan goal and consolidates commitment. In the last two sessions, the CHW will review the change plan, continue to elicit and reinforce change talk, problem-solve barriers, consolidate commitment, and consider strategies to maintain behavior change.
Study NCT04459897 — intervention group
Intervention type: OTHER
Intervention: Evaluation of epithelioid and gigantocellular granulomas within the hepatic parenchyma by histopathology approach.
Description: : Retrospective histopathology review done by an expert of histopathology analysis (DAPI cell labeling). Analysis of the percentage of epithelioid cells and the percentage of gigantocellular granulomas in hepatic parenchyma of patient diagnosed for Hepatitis Granulomatous
Study NCT03273907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract surgery, followed by implantation of the CyPass Micro-Stent in one eye (the study eye) at the surgery visit
Study NCT03540420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: atezolizumab 1200 mg intravenous every 3 weeks in 12 months
Study NCT02213614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lithium Water
Description: Supply daily doses of Lithium water in form bottled mineral water
Study NCT01895699 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Contrast agent
Study NCT01895699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast agent
Study NCT03674034 — intervention group
Intervention type: OTHER
Intervention: CTscan and MRI images
Description: CTscan and MRI images segmented according to procedures previously developed by GRAMFC
Study NCT02213614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo: spring mineral water
Description: Drink spring natural water a placebo 3 times a day
Study NCT02213614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: natural spring water
Description: A group will drink natural spring water for 4 months
Study NCT00296036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pyridoxine hydrochloride
Description: Given orally
Study NCT00296036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urea/lactic acid-based topical cream
Description: Applied topically
Study NCT00296036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally or applied topically
Study NCT00296036 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally or applied topically
Study NCT01189331 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: CT coronary angiography and computational fluid dynamics
Description: Evaluate coronary blood flow dynamics by CT coronary angiography and computational fluid dynamics
Study NCT03688360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: . Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy, formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises.
Study NCT03195504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: High flow nasal oxygen (60 l) under GA
Study NCT03195504 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CON (control)
Description: Standard oxygen (10-15 l) under GA
Study NCT02266563 — intervention group
Intervention type: DRUG
Intervention: Amyvid PET Scan
Description: A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.
Study NCT04553861 — intervention group
Intervention type: DEVICE
Intervention: Galaxy Watch Active2
Description: Every 1 hour by subject (on-demand) from 7 AM to 10 PM and every 5 minutes (automatic) from 10 PM to 7 AM
Study NCT02266563 — intervention group
Intervention type: DRUG
Intervention: T807 PET scan
Description: Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.
Study NCT03018158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: denture wear.
Description: MR Imaging was collected with or without denture wear.
Study NCT02472249 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT perfusion
Description: Two dynamic CT perfusion acquisitions of the whole liver will be performed with a 320-detectors CT, prior and after to the norepinephrine injection.
Study NCT02472249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine intra-arteriel/hepatic
Description: A small dose (24 ug) of norepinephrine will be injected in the hepatic artery over 10 seconds. The half-life of the drug is 90 seconds..
Study NCT00186628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation
Description: Total lymphoid irradiation (TLI) administered at 80cGy for 10 days
Study NCT00186628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 administered as an intravenous (IV) infusion once weekly for 4 doses.
Study NCT00186628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymoglobulin, rabbit (ATG, rabbit ATG)
Description: Rabbit anti-thymoglobulin (ATG) administered from Day -11 through Day -7 (5 doses) at 1.5 mg/kg/day, for a total dose of 7.5 mg/kg.
Study NCT00186628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine (CSP) administered orally at 6.25 mg/kg twice-a-day (BID) from Day -3 until through Day +56 post-peripheral blood progenitor cell (PBPC) infusion. Dose may be adjusted to maintain a therapeutic level of cyclosporine, or in response to renal insufficiency. If at Day +56, chimerism assessment demonstrates > 40% donor cells in the CD3+ lineage, and the patient is without evidence of GvHD, then cyclosporine taper will begin (6% reduction per week).
Study NCT00186628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenylate mofetil
Description: Mycophenylate mofetil (MMF) will be administered at 15 mg/kg po Day 0, at 5 to 10 hours after mobilized PBPC infusion is complete
Study NCT01745705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Spine Manipulation
Study NCT01745705 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manual Contact
Study NCT04446000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A solution matching the excipient profile of CSL730 without the active substance
Study NCT03533868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care viral load monitoring test
Description: For enumerating viral load for patients in the POC arm, we will use the Cepheid Xpert® HIV-1 Viral Load test, a quantitative assay with a quantification range of 40 to 10,000,000 copies/mL. Based on the GeneXpert® technology, Xpert HIV-1 VL automates the test process, including RNA extraction, purification, reverse transcription and cDNA real-time quantitation in one fully integrated cartridge. The pre-loaded disposable single-use cartridges provide a visual read-out within 90 minutes. The assay requires 1 mL of plasma using a precision pipette (1.2 mL using a transfer pipette).
Study NCT00186628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim provided as needed for neutrophil support
Study NCT00186628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: Granisetron administered as an anti-nausea agent (anti-emetic) at 1 mg orally 30 to 60 minutes before TLI
Study NCT00186628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solumedrol
Description: Solumedrol, an anti-inflammatory glucocorticoid containing methylprednisolone sodium succinate, administered at 1 mg/kg as a premedication for anti-thymoglobulin (ATG)
Study NCT00186628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen administered orally at 650 mg 1 hour prior to infusion of PBPC